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ABSTRACT
Background: Antipsychotic medications are the first-line treatment for schizophrenia.
Medication non-adherence is often a problem among patients with schizophrenia, leading
to relapse, rehospitalization, and high cost-burden. First-generation antipsychotics were
first developed to treat schizophrenia; however, the higher risk of extra-pyramidal side
effects have made them unfavorable in comparison to second-generation antipsychotics
(SGA). Nevertheless, antipsychotic adherence is often suboptimal, which can lead to
relapse and rehospitalization. Long-acting injectable (LAI) antipsychotics were
developed to help improve adherence, thereby reducing rates of relapse. However, this
drug class is associated with high treatment cost while the more common oral
antipsychotics are inexpensive in comparison.
Methods: Data from Optum’s de-identified Clinformatics Data Mart Database from
years 2010-2015, was utilized to conduct a retrospective cohort study and costeffectiveness analysis comparing the outcomes and cost of LAI second-generation
antipsychotics (SGAs) with oral SGAs for the treatment of schizophrenia. Patients with a
history of at least two inpatient hospitalizations for schizophrenia two years prior to a
recent relapse hospitalization (index date) during 2012-2014 were identified. Patients
were required to have a claim for a LAI SGA or oral SGA within 40 days of discharge
from the index hospitalization. Patients were entered into a 12-month follow-up period
during which medication cost, adherence, and medication switch or rehospitalization due
to relapse were measured. A patient level descriptive analysis was conducted followed by
developing a decision model for which an incremental cost-effectiveness ratio (ICER)
was estimated comparing incremental cost of treatments and incremental effectiveness.

Results: 158 patients met the study’s inclusion-exclusion criteria. Of 158 patients, 135
(85.4%) had a claim for an oral SGA within 40 days of index discharge and 23 (14.6%)
had a claim for a LAI SGA. The mean age of the population was 48-years (standard
deviation, SD +12.0) with similar distribution observed in gender (49.4% female).
Patients experienced about 4 hospitalizations (SD +2.7) on average, prior to their index
date and also had a mean index length of stay of about 10 days (SD +8.8). Compared to
patients receiving oral SGAs, patients receiving LAIs experienced numerically higher
adherence rates, numerically higher proportion of stable patients, and higher mean cost of
medication ($1,339.20 vs. $282.90, p<.0001). A sensitivity analysis determined that
change in the proportion of adherent patients prescribed LAIs had a large impact on the
ICER value.
Conclusion: Although statistically not significant, the LAI cohort was associated with
numerically lower rates of switch or rehospitalization and a higher proportion of adherent
patients compared to oral SGAs. While LAIs are associated with a much higher average
monthly cost than their oral comparators, the decision analysis indicated that the
additional expenditure was associated with improvement in the measured outcome.
Further research is warranted examining populations with higher prevalence of
schizophrenia to provide larger sample sizes and to measure cost-benefit, which may
illustrate cost-avoidance through the cost of rehospitalization due to relapse.
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CHAPTER 1
INTRODUCTION
Schizophrenia is a lifelong, incurable, mental disorder that affects about 1% of the
United States’ population.1 Schizophrenia typically develops in late adolescence to young
adulthood and tends to occur earlier in males than in females.1 Patients with
schizophrenia may experience “positive” symptoms including delusions, hallucinations
and cognitive dysfunction as well as “negative” symptoms such as reduced expression
and motivation.1 Such symptoms often put patients out of touch with reality and lower
their mental awareness. Many patients turn to substance abuse as means to cope and selfmedicate. Patients with schizophrenia have about five times higher rate of tobacco
smoking than that found in the general population2 and have higher prevalence of illicit
drug use.3 Patients also live with a 5% suicide risk1 and are twelve times as likely to die
from suicide compared with the general world population.4 Because of these factors and
disease exacerbations, schizophrenia is associated with an increased mortality rate5 and a
decrease in life expectancy of about 14.5 years compared to the average world
population.6
Antipsychotic medications are used as first-line treatment for schizophrenia in
order to manage and control disease symptoms. There are first-generation (typical) and
second-generation (atypical) antipsychotics. First-generation antipsychotics (FGAs), such
as haloperidol or fluphenazine, are directly associated with extrapyramidal side effects
such as tardive dyskinesia, drug induced parkinsonism and dystonias.7-9 Secondgeneration antipsychotics (SGAs) have a decreased risk of extrapyramidal side effects
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and hence may be preferred by patients. SGAs are also prescribed more frequently than
first-generation antipsychotics.10
Schizophrenia is a mental illness frequently seen in hospitals across the country.
In 2010, schizophrenia was the second most hospitalized mental illness 11 and in 2014, the
second most common hospital visit among any inpatient stay occurring in 18-44 years
age group (excluding maternal or neonatal principal diagnoses).12 Due to frequent
hospitalizations, schizophrenia can cause substantial burden to the US healthcare
system.13,14 Due to the severity of the disease, relapses are common in patients with
schizophrenia. Patients who relapse are associated with high hospitalization rates and
cost15 and patients with a history of relapse are associated with an even higher cost
burden than those who do not experience relapses.16
Relapse rates are often influenced by medication adherence,17 with low
medication adherence being the leading cause of relapse in psychosis.18 Despite the direct
correlation between relapse and non-adherence, adherence rates among patients with
schizophrenia are often suboptimal.19-21 In order to address the difficulties in adhering to
oral therapies and provide better outcomes, long-acting injectable antipsychotics (LAIs)
were developed as an intra-muscular depot injection given by a clinician or pharmacist.
Each dose can provide two-weeks to one-months’ worth of medication or more,
potentially substituting 30 or more pills with one injection. LAIs are intended increase
adherence and therefore decrease the potential of relapse and hospitalization. The first
LAI SGA was approved in 2003, and these formulations increasingly began to become
recognized for their usefulness in chronic patients.22 With additional LAIs being
developed throughout the years, LAIs demonstrated their effectiveness in reducing
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relapse rates and increasing patient adherence.23-26 However, the high cost of newer LAIs
may prevent patients from receiving this beneficial treatment.27
Several cost-effectiveness studies have been conducted comparing LAIs to oral
antipsychotics. One non-US study conducted in Portugal compared the costs and
effectiveness of oral olanzapine to LAI risperidone, paliperidone, and haloperidol. 25 A
decision model with adherence rates were utilized with a one-year timeframe. Outcomes
of inpatient hospitalization due to relapse, emergency room admission, and stability were
assessed. The authors reported that patients utilizing LAI paliperidone had a lower rate of
relapse or emergency room admission and a higher cost than oral olanzapine. Although
comprehensive, their study poses limitations that can be improved upon. As such this was
a non-US study, therefore findings cannot be applied to the US population and US
payers. The authors state that the model inputs used were based on various pieces of
literature and clinical trials, this in return may limit its real-world applicability as data is
not taken from a population sample or database.
A Medicaid-based study analyzed the cost-effectiveness of paliperidone LAI to
oral antipsychotics.28 The model utilized a decision model and was used to inform
outcomes in stable patients over a 12-month period. The authors found that paliperidone
LAI was associated with higher adherence and was projected to decrease psychiatric
hospitalizations compared to oral antipsychotics. The authors state that paliperidone LAI
substantially decreases costs over an 18-month period. However, the cost of medication
was not incorporated into the model, instead the findings are reported with the potential
cost prevented by implementing LAIs in comparison to oral antipsychotics. Data from
this study was also obtained from three separate clinical trials, which may not represent a
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real-world sample as patients are subject to strict inclusion and exclusion criteria and are
often observed for a limited period of time. Two of the trials were also conducted
globally and were subject to very different designs, according to the authors.
Another cost-effectiveness study that compared LAIs to an oral antipsychotic was
a decision model comparing LAI olanzapine to LAI risperidone, LAI paliperidone, LAI
haloperidol, and oral olanzapine.26 The model was developed with a one-year time
horizon, analyzing adherence rates and probability of relapse. LAI olanzapine was
associated with lower inpatient and outpatient relapses and higher proportion of stable
patients. LAI olanzapine had lower cost and better outcomes when compared to the other
LAIs measured, however, oral olanzapine was associated with poorer outcomes but a
lower cost. Similar to the Portugal study, the authors utilized literature and expert opinion
to determine model inputs. The study also measured medication adherence as an initial
characteristic of patients starting therapy, not accounting for possible changes in
adherence throughout the model.
Our study sought to improve upon the limitations of previous cost-effectiveness
studies by analyzing LAIs and oral antipsychotics using claims data from a large
commercial insurer in the US. Patients with schizophrenia are representative of a realworld sample and model inputs are directly derived from an administrative claims
database, limiting the potential of bias associated with obtaining model inputs from
within the literature, as inputs are often derived from multiple sources and different study
samples. Utilizing a retrospective database also allows for continuous measurement of
recurring variables, such as adherence, within a defined follow-up period. This study is
also not industry funded, which excludes the potential of conflict of interest.
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The objective of this study was to evaluate the cost-effectiveness of LAI
antipsychotics, specifically atypical antipsychotics, as an alternative to oral SGAs in the
prevention of rehospitalization due to relapse or medication switch, for the treatment of
schizophrenia from a third-party payer perspective.

5

CHAPTER 2
METHODS
Study Design & Data Source
A pharmacoeconomic analysis was conducted using data from a retrospective
claims US-based database, in order to describe the utilization and cost-effectiveness of
oral and LAI second-generation antipsychotic medications among patients with
schizophrenia.
Optum commercial claims database was utilized to complete this study. Optum’s deidentified Clinformatics Data Mart Database29 is an administrative healthcare claims
database for members of a national managed care commercial health insurer. Optum
includes pharmacy claims, medical claims, lab results, standard pricing, member
demographic, and inpatient confinement data. Inpatient claims are coded utilizing
International Classification of Disease, 9th and 10th Revision, Clinical Modification (ICD9-CM, ICD-10-CM). Medical claims are coded with ICD-9, ICD-10, and Healthcare
Common Procedure Coding System (HCPCS) codes. Pharmacy claims use the National
Drug Code (NDC) coding system for prescription drug claims. All records and claims
within the database are de-identified. This study utilized data from years 2010-2015.
Study Population
The study population consisted of patients with an inpatient claim of a primary
diagnosis of schizophrenia (ICD-9 295*) identified during the years 1/1/201211/21/2014. The most recent hospitalization during the timeframe was labeled as a
patient’s “index hospitalization.” In addition, patients were also required to be
continuously enrolled for at least two years before and one year and 40 days after the
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index date. The exposure period was defined as any patient prescribed a LAI SGA or oral
SGA within 40-days after discharge from their index hospitalization within the index
period of 1/1/2012-11/21/2014. Patients not within the age range of 18 to 64-years on
their index date were excluded from this study as well as patients with a LAI SGA claim
prior to their index date. Patients with extensive inpatient care, defined as over 60-day
length of stay, as their index hospitalization were excluded as the service provided to
these outlier patients would likely be relatively distinct from the rest of the population.30
Figure 1 depicts the patient flow chart with the inclusion and exclusion criteria, while
Figure 2 depicts the study schematic diagram. Patients prescribed a LAI or oral dosage
form of the LAI SGAs listed in Supplemental Table 1 were included in the study.
Patients were categorized into two cohorts, oral SGA or LAI SGA based upon
their drug claim during the exposure period.
Study Measures
The endpoints in this analysis were rehospitalization due to relapse, switching
from exposure medication without rehospitalization due to relapse, or completion of the
405-day follow-up period without switch or rehospitalization. Rehospitalization due to
relapse was defined by any hospitalization within 405 days from a patient’s index date
with a primary diagnosis of schizophrenia (ICD-9 295* or ICD-10 F20*, F25*). The
follow-up for these patients ended on their date of rehospitalization. Switching
medications was considered to be lack of effectiveness or tolerability provided by the
exposure drug. This was defined as a patient discontinuing their exposure medication for
at least 60 days after the remainder of available supply from the last exposure drug fill
date.31,32 The follow-up for patients who switched medications concluded on the first
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claim of any non-exposure antipsychotic after exhausting the remaining supply of their
exposure antipsychotic. Patients with a 60-day gap but failing to have a claim for a nonexposure antipsychotic before the end of follow-up were not considered to switch, the
days without an antipsychotic medication contributed to the patient’s adherence rate.
Upon rehospitalization, switch, or completion of follow-up, adherence rates were
calculated. Adherence rates were calculated using medication possession ratios (MPR)
and is only representative of adherence to the exposure drug. MPR was calculated as the
ratio of the total number of nonoverlapped days covered by antipsychotics during the
follow-up period, over the total days until relapse from index hospitalization, switch, or
end of follow-up (405 days).33 Rehospitalization due to relapse was the primary outcome
assessed in this study and was measured prior to switching medications. However, if a
patient were to switch treatments before relapse, their adherence rates were calculated
until switch. Adherence was categorized using MPR thresholds of ≥0.8 and <0.8.
Acceptable adherence has been defined by others as an MPR ratio of 0.8 or above, with
poor adherence below 0.8.18, 19
Cost of Medications
Optum data includes a “standard price” as the cost of a claim, which represents
the total amount paid by the insurer plus the amount paid by the patient for a medication,
procedure, medical visit, inpatient stay or other healthcare service. Patient copays,
deductibles, and dispense fees were subtracted out from the standard price to obtain the
medication cost incurred by the third-party payer. Patients with schizophrenia may be coprescribed multiple types of antipsychotic medication along with their exposure
medication, therefore, the medication cost calculated in this study is reflective of any
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antipsychotic use during the follow-up period. LAI administration costs were included in
the treatment costs as well. Cost was calculated by dividing total cost of medication by
total follow-up days. Costs for patients with a 60-day medication gap without another
antipsychotic claim during follow-up were measured until the date of their last exposuredrug claim plus the remaining days’ supply. Cost was multiplied by 30 days to present a
monthly figure.
Gender, age, region, insurance status, health plan type, number of prior
hospitalizations, and index hospitalization length of stay were utilized as covariates for
this analysis.
Statistical Analyses
A patient level descriptive analysis was conducted to evaluate the differences in
baseline characteristics between the LAI and oral antipsychotic cohorts (Table 1). Rates
of adherence and medication switching were measured and compared. The mean cost of
medication, days of follow-up, age, number of prior hospitalizations, and the index
hospitalization length of stay was calculated and compared between the two study cohorts
using chi-squared and t-tests. The mean cost of medication between the two cohorts were
compared as log-transformed costs and analyzed utilizing a t-test for independent
samples.
A decision tree was developed to determine the cost-effectiveness of LAI versus
oral therapy accounting for patient adherence rates (Figure 3). Branches were constructed
as the proportion of patients that were adherent or non-adherent per cohort. The
probability of adherent or non-adherent patients remaining stable in follow-up (no
rehospitalization or medication switch) was applied. A third-party payer perspective and
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one-year time-horizon were utilized. The decision tree was modeled and analyzed using
TreeAge Pro 2019, R1©.34
Study Outcomes
The decision analysis defined a combined outcome representing a “stable” patient
as having no rehospitalization due to relapse or switching of treatment during the followup period. This outcome was evaluated according to level of medication adherence using
MPR and across treatment cohorts listed in Table 2.
Establishing which treatment type was more cost-effective was calculated through
an incremental cost-effectiveness ratio (ICER). The numerator of the ICER value
represented the difference in mean cost of medication and the denominator represented
the difference in exposure drug effectiveness (percentage of patients who neither
switched regimen nor experienced a rehospitalization due to relapse, i.e. stable patients).
A deterministic sensitivity analysis was conducted using TreeAge Pro 2019,
R1©.34 A tornado diagram was developed to address uncertainty within the model. The
analysis illustrates variations in the input parameters that affect the calculated ICER value
such as increasing the proportion of adherent patients receiving LAIs to 100% and
decreasing proportion of adherent patients receiving oral SGAs to 0%. All drug cost
inputs for both LAI and oral treatment groups were adjusted by 50%.
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CHAPTER 3
RESULTS
A total of 5,312 patients with schizophrenia were identified during the index
period. After applying the pre-index, follow-up and age criteria, 631 patients were
identified; 291 patients were excluded who did not have a pharmacy dispensing for an
SGA or LAI SGA during the 40-day exposure period following discharge from the index
hospitalization, 157 patients were excluded who received a LAI SGA prescription before
their index hospitalization or who were deemed to have extensive inpatient use. An
additional 25 patients who received oral aripiprazole as an exposure drug or switched to
LAI after the exposure period, were removed. Only patients with an oral medication for
which a LAI form was available were included and because no patients in the LAI cohort
received aripiprazole, these patients were excluded. The final population included 158
patients (Figure 1).
Descriptive analysis
The mean age of the study population upon index hospitalization was 48-years
(standard deviation, SD +12.0) with similar distribution observed in gender (49.4%
female). The majority of patients were covered by Medicare (81.7%) and were located in
the Midwest or South regions (69.0%) of the US. Patients experienced about 4
hospitalizations (SD +2.7) on average, prior to their index date and had a mean index
length of stay of about 10 days (SD +8.8) (Table 1).
A total of 135 (85.4%) patients were classified to the oral antipsychotic cohort
and 23 (14.6%) patients to the LAI cohort. Age distribution was similar in both cohorts,
with an average age of 48.5 years (SD +12.4) for patients in the oral antipsychotic cohort
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and 48.4 years (SD +10.0) for patients in the LAI cohort (p=0.94). Patients in the LAI
cohort were more likely to be male than those in the oral antipsychotic cohort.
Distributions of mean index length of stay (9.9 vs. 9.5 days, p=0.82) and mean prior
hospitalizations (3.2 vs. 3.7 days, p=0.23) were similar between the LAI and oral cohorts,
respectively. Patients in the oral antipsychotic cohort had about 310 days (SD +127.3) of
follow-up on average, compared with an average of 299 days (SD +135.3) for the LAI
cohort (p=0.69).
Outcomes
Of the 135 patients receiving oral antipsychotics, 67 (49.6%) were prescribed
risperidone and 61 were prescribed (45.2%) olanzapine during the exposure period. The
other 23 patients all received a LAI SGA.
Compared to patients receiving oral antipsychotics, patients receiving LAIs
experienced a higher proportion of adherent patients and higher proportion of stable
patients, although these differences were not statistically significant. Patients receiving
LAIs had a higher mean monthly cost of medication ($1339.20 vs. $282.90, p<.0001).
The statistical comparison for costs involved log transformed values as the skewness and
kurtosis values for non-transformed costs were relatively high (LAI: 3.46, 12.46 ; PO:
2.11, 4.21, respectively). Skewness and kurtosis for log-transformed values were
calculated at 2.93 and 9.57 for LAI costs and 0.26 and -0.92 for oral costs, respectively.
Adherence and cost figures are presented in Table 2 and Table 3.
The decision tree captured costs for patients according to a level of adherence and
the combined endpoint of medication switch or rehospitalization, as compared with not
experiencing either of these outcomes (i.e. remaining stable) during follow-up. The
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branch probabilities and costs are shown in the decision tree in Figure 3. The mean costs
for the oral and LAI cohorts after implementing adherence and state probabilities, were
estimated to be $259.91 and $1322.04, respectively.
Sensitivity Analysis
A deterministic sensitivity analysis was conducted to address uncertainty within
the developed decision tree model. Adherence and cost inputs were modified to illustrate
changes in the ICER value. Figure 4 addresses multiple variations on the range of the
base-values in the decision model that would make the ICER value more or less favorable
for LAIs. The diagram included increased LAI adherence (proportion of adherent patients
increased to 100%), decreased oral adherence (proportion of adherent patients decreased
to 0%), and a 50% decrease and increase to all treatment costs. The sensitivity analysis
suggests that a minor increase in the proportion of adherent patients receiving LAIs, leads
to a lower ICER value and improved treatment value.

Discussion
This study applied a retrospective cohort analysis using a real-world sample
obtained from Optum’s de-identified Clinformatics  Data Mart Database
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to examine

the cost and outcomes of two different medication classes, oral SGAs and LAI SGAs, in
patients with schizophrenia. Patients with a history of inpatient hospitalizations were the
primary focus of this study as LAIs have often been intended for patients that have more
severe forms of schizophrenia or patients with a history of relapse and non-adherence.35
Therefore, we required that all patients were required to have at least two inpatient
hospitalizations for schizophrenia prior to their index hospitalization. Although guidance
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is limited on this criterion of two or more prior hospitalizations, it was necessary to help
narrow the cohort to patients who are more likely to be prescribed LAIs and achieve a
disease severity that was similar between the oral and LAI treatment groups. Despite the
large population for study provided by the data source, after the application of our
inclusion criteria only a small number of cases remained for our analysis. This
necessitated the combining of the study outcomes of rehospitalization and medication
switch into a composite outcome, and also diminished statistical power when evaluating
between-group differences.
The ICER value was calculated through the decision tree to incorporate the
impact of medication adherence and to assess the incremental cost required for an
additional outcome of interest associated with the use of LAIs over oral SGAs. According
to the Institute for Clinical and Economic Review, an ICER ratio often uses quality
adjusted life years (QALY) as the measure of effectiveness (denominator) to assess
value.36 However, our study did not aim to measure long-term survival or impact on
patient quality of life, and thus QALY was not measured. The denominator of the ICER
ratio in our study was representative of the numerical difference in the proportion of
stable patients between the LAI and oral treatment groups. Willingness to pay (WTP)
thresholds are often used when calculating ICER values to determine if a treatment is a
cost-effective alternative to the comparative treatment. The Institute for Clinical and
Economic Review recommends US based studies use WTP thresholds of $50,000$150,000 per QALY to guide considerations for the value of the alternative treatment
option.36 However, other similar studies have reported ICER results using QALY as the
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outcome measure,25,26,40 and we were unable to find any published data describing
thresholds for willingness to pay for treatment stability in schizophrenia.
Interpreting ICER values between studies can be difficult due to variation in how
cost and effectiveness inputs are derived. Previous studies have demonstrated estimated
ICERs of about $14,500/QALY and $26,800/QALY (to their respective study years)
when comparing LAIs to oral SGAs.25,26 However, QALY was utilized as an
effectiveness measure and drug treatment costs were combined with inpatient, outpatient,
and rehabilitation clinic costs. Therefore, a direct comparison of ICER values may not be
accurate. While our study did not incorporate non-pharmacological treatment costs, we
did measure all antipsychotic use to represent an average monthly cost categorized under
the exposure medication sub-groups. One US-based study analyzed the antipsychotic
medication costs of LAI risperidone and oral SGAs in a clinical trial in 2009. The cost of
LAI risperidone including other antipsychotic medications was estimated to be over
$1900 per quarter for an estimated monthly cost of approximately $650. Oral SGAs
including other antipsychotic medications was estimated to be $1150 or approximately
$380 per month.37 Although this study illustrates just under a twofold increase in cost
when comparing LAI risperidone and oral SGAs, our study suggests that LAI risperidone
and other LAI SGAs are associated with an even higher cost when compared to oral
agents.
Adherence can be measured in a number of ways. As discussed, we utilized MPR
to assess adherence in our study. Mean adherence was not calculated, instead patients
were classified into adherent (>0.80) or nonadherent (<0.80) categories based on their
individual MPR in the follow-up period. While this does not represent the exact
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adherence rate a patient may experience with a LAI SGA or oral SGA, dichotomizing the
adherence measure is a common approach in the literature. Moreover, classifying
adherence in categories allows for the calculated proportions to be analyzed within a
decision tree. This is a common method when incorporating adherence into a costeffectiveness analysis with a decision model, as prior studies suggest.25,26,40
Switching antipsychotic treatment is common among patients with schizophrenia.
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, a large
multi-site, nationwide, trial, assessed the effectiveness of oral antipsychotic medication in
1,493 patients with chronic schizophrenia.38 It was found that on average, 74% of the
study population discontinued the study medication within 18-months due to efficacy or
intolerability. In our study, 29% of patients discontinued their exposure antipsychotic
medication and started on another non-exposure antipsychotic and about 15%
discontinued their exposure medication but did not start another antipsychotic medication
(not classified as switch). While these rates cannot be directly compared to results from
the CATIE study due to differences in follow up time, study population, and other
factors, our results nevertheless corroborate that a substantial proportion of patients do
not persist with the prescribed medication.
A deterministic sensitivity analysis was conducted to assess uncertainty within the
decision model (Figure 4). It was determined that any change in the proportion of
adherent patients has a large impact on the ICER, specifically the proportion of patients
adherent to LAIs. Due to the small numerical difference in incremental effectiveness at
base-case inputs, the value becomes highly sensitive to any change in a path probability.
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To better illustrate the change in the ICER value by LAI adherence, a one-way sensitivity
analysis of the proportion of adherent patients receiving LAIs was conducted (Figure 5).
In spite of the established clinical benefits LAIs offer to patients with
schizophrenia, this class of antipsychotics is still prescribed much less frequently than
their oral comparators. Only about 15% (n=23) of the study population was prescribed
LAIs in our study. One recent claims-based study that utilized Truven Health Analytics
MarketScan Medicaid data from 2010-2013, measured the outcomes of LAIs compared
to oral antipsychotics in patients with schizophrenia. Patients were required to have a
recent (6-month) history of non-adherence. Out of about 4,000 patients that met inclusion
criteria, the researchers identified 340 users of a LAI antipsychotic (about 9%) within 30
days of their index hospitalization. Of those patients, only 183 patients (about 5%) were
prescribed a LAI SGA (risperidone or paliperidone).32 Another claims-based study
assessing the effectiveness of LAIs in comparison to oral agents found that about 15% of
LAI naïve patients were initiated on any LAI with about 7% initiating a LAI SGA.39
Future studies are warranted that explore the boundaries around the accessibility and
prescribing inclinations of LAIs, specifically LAI SGAs.
Limitations
This study has multiple limitations that warrant discussion. Due to the
retrospective and observational nature of this study, it is subject to selection bias. This
was mitigated through detailed inclusion and exclusion criteria that yielded two similar
cohorts. Adherence was limited to the information provided with the pharmacy claims
data and is only representative of the exposure medication. Patients with gaps in their
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exposure drug claims were assumed to be non-adherent. Data describing medication use
and treatment during inpatient visits were not available with the data source used.
The sample size of our study was relatively small, which therefore diminishes
statistical power when evaluating differences between the two treatment groups. We were
also unable to identify any patients that received LAIs administered in outpatient clinics.
HCPCs codes were utilized in addition to NDC codes to account for such patients,
however, this did not yield additional patients. Despite a small sample size, the rate of
which patients are prescribed LAIs is accurate and comparable to previous US claimsbased studies.32,39 To detect a statistically significant difference between the effectiveness
values of both treatment cohorts measured in our study, it is suggested that the population
size of the LAI and oral cohorts be approximately 2,500 and 14,700 patients,
respectively.
Cost of treatment can be difficult to capture when measuring adherence, as
patients who are nonadherent will have lower costs than those who are not. To attempt to
control for this issue, patients without an exposure drug claim 60 days after their last
days’ supply were identified and their costs were measured from the first claim of the
exposure drug to the last claim of the exposure drug. However, patients with smaller gaps
between exposure medication fills were not accounted for when measuring cost. Average
monthly cost is also representative of any antipsychotic use as many patients with
schizophrenia received multiple antipsychotic medications on a monthly basis. Patients
prescribed LAIs also typically receive the oral dosage form of the drug along with their
injectable, which is an added cost that needed to be captured. Costs are presented in their
respected years of payment, as they were not adjusted for inflation.
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This study also does not include aripiprazole LAI as it was approved by the US
Food and Drug Administration in 2013.41 Patients are more likely to be prescribed other
LAI SGAs that were available before the release of aripiprazole LAI (paliperidone,
olanzapine, or risperidone) as many patients’ index discharge dates were around the time
of approval. Patients with an exposure drug claim for oral aripiprazole were removed to
make the two cohorts more comparable.
Lastly, this model is limited to a one-year timeframe, however, incorporating a
longer timeframe is challenging given the disease pathway and a higher rate of patients
switching their medication is likely to occur.38 This makes it furthermore challenging to
measure outcomes over a longer time period. However, a one-year follow-up period is
common in cost-effectiveness studies for evaluating the short-term outcomes of newly
initiated LAI antipsychotic therapy.25,26,35,40
Despite these limitations, we believe that this is the first cost-effectiveness
analysis comparing LAI SGAs to oral SGAs with Optum data. Providing insights into
both public and commercially insured patients, as a contrast with only publicly insured
patients, which comprises much of the extant literature.
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CHAPTER 4
CONCLUSION
This study offers real-world evidence for the use of LAI SGAs. Although
statistically not significant, the LAI cohort was associated with numerically lower rates of
switch or rehospitalization and a higher proportion of adherent patients compared to oral
SGAs. Although LAIs are associated with a much higher average monthly cost than their
oral comparators, their intended benefit to prevent medication switch or relapse was
modeled in our study. However, due to the small sample size and statistically nonsignificant results, these findings may not be sufficiently precise. We recommend that our
findings not be used for policy decisions. Further research is warranted with a larger
sample size and in terms of cost-benefit, which can illustrate cost-avoidance through the
cost of rehospitalization due to relapse. With the potential for further expansion of new
agents in the LAI antipsychotic class, generic drug development, and increased
awareness of the benefits provided by LAIs, treating a chronic mental illness like
schizophrenia, will become more efficient and less expensive.
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APPENDIX
Table 1. Baseline demographics of patients with schizophrenia (*Cell counts <11)
Total (n=158)
PO (n=135)
LAI (n=23) PO vs. LAI
n
Age at index, years
18-39
40-49
50-59
60<
Gender
Male
Female
Region
Northeast
Midwest
South
West
Insurance
Medicare
Commercial
Product
Health Maintenance Org.
Other
Prior Hospitalizations
2
3-5
5<
Index length of stay, days
1-5
6-10
10<

%

n

n

%

p Value

33
39
57
29

20.89
24.68
36.08
18.35

28
31
50
26

20.74
22.96
37.04
19.26

*
*
*
*

*
*
*
*

80
78

50.63
49.37

67
68

49.63
50.37

*
*

*
*

18
47
62
31

11.39
29.75
39.24
19.62

15
40
56
24

11.11
29.63
41.48
17.78

*
*
*
*

*
*
*
*

129
29

81.65
18.35

108
27

80.00
20.00

*
*

*
*

76
82

48.10
51.90

66
69

48.89
51.11

*
*

*
*

67
73
18

42.41
46.20
11.39

57
63
15

42.22
46.67
11.11

*
*
*

*
*
*

56
50
52

35.44
31.65
32.91

52
45
38

38.52
33.33
28.15

*
*
*

*
*
*

Total (n=158)

Age at index, years
Prior Hospitalizations
Index length of stay, days
Follow-up, days
Switch
Relapse

%

Mean
48.4
3.63
9.53
308.57
175.57
223.25

PO (n=135)

Std Dev
Mean
11.96 48.54
2.74
3.70
8.75
9.50
128.12 310.24
115.61 184.32
128.53 220.11
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LAI (n=23)

Std Dev Mean
12.4 48.35
2.90
3.22
9.10
9.91
127.32 298.83
119.54
*
131.26
*

Std Dev
9.97
1.44
6.58
135.25
*
*

0.94
0.23
0.82
0.69

Table 2. Results: Adherence, stability, medication switch, and relapse (*Cell counts <11)
PO (n=135)
LAI (n=23)
>0.80
<0.80
>0.80
<0.80

Total
Stable
Switch
Relapse

n
81
53
19
*

%
60.00
67.95
50.00
*

n
54
25
19
*

%
40.00
32.05
50.00
*

n
*
*
*
*

%
*
*
*
*

n
*
*
*
*

%
*
*
*
*

Table 3. Monthly cost of antipsychotic treatment, $ (*Cell counts <11) (^log transformed)
PO (n=135)
LAI (n=23)
PO vs. LAI^
Mean
Std Dev
Mean
Std Dev
p Value
Total
282.90
432.63
1339.20
694.07
Risperidone
152.10
252.61
902.40
239.06
Olanzapine
363.90
515.45
*
*
Paliperidone
930.60
409.65
1466.10
753.56
<.0001
Stable
315.00
402.88
1296.00
710.30
Risperidone
160.20
183.22
1180.80
224.10
Olanzapine
408.90
490.39
*
*
Paliperidone
1080.00
680.32
1315.80
767.59
<.0001
Switch
312.00
549.40
1504.20
739.71
Risperidone
162.90
180.08
616.50
190.51
Olanzapine
348.00
656.16
*
*
Paliperidone
701.70
392.30
1760.40
569.60
<.0001
Relapse
65.40
180.08
*
*
Risperidone
42.90
134.22
*
*
Olanzapine
69.00
65.97
*
*
Paliperidone
*
*
*
*
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Supplementary Table 1. Currently available LAI atypical antipsychotics
Proprietary Name Generic Name Release to Market Dosage
Abilify Maintena
Aripiprazole
March 2013
300mg/month (deltoid/gluteal)
400mg/month (deltoid/gluteal)
Aristada
Aripiprazole
October 2015
441mg/month (deltoid/gluteal)
662mg/month (gluteal)
882mg/month or 6 weeks (gluteal)
1064mg/2 months (gluteal)
Zyprexa Relprevv
Olanzapine
December 2009
105mg/2 weeks (gluteal)
210mg/2 weeks (gluteal)
300mg/2 or 4 weeks (gluteal)
405mg/2 or 4 weeks (gluteal)
Invega Sustenna
Paliperidone
July 2009
39mg/month (deltoid/gluteal)
78mg/month (deltoid/gluteal)
117mg/month (deltoid/gluteal)
156mg/month (deltoid/gluteal)
234mg/month (deltoid/gluteal)
Invega Trinza
Paliperidone
May 2015
273mg/3 months (deltoid/gluteal)
410mg/3 months (deltoid/gluteal)
546mg/3 months (deltoid/gluteal)
819mg/3 months (deltoid/gluteal)
Risperdal Consta
Risperidone
October 2003
12.5mg/2 weeks (deltoid/gluteal)
25mg/2 weeks (deltoid/gluteal)
37.5mg/2 weeks (deltoid/gluteal)
50mg/2 weeks (deltoid/gluteal)
Perseris Kit
Risperidone
August 2018
90mg/month (SC abdominal)
120mg/month (SC abdominal)
SC: Subcutaneous
Information obtained from www.fda.gov41 and package inserts
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Figure 1. Study sample selection flow chart
8,899 All patients with an inpatient
schizophrenia diagnosis in 20102015
3,587 Excluded patients without an
inpatient diagnosis during index
period 1/1/12-11/21/14
5,312 Patients with a schizophrenia
index-hospitalization between
1/1/2012 – 11/21/2014
1,102 Excluded patients who were
not within age 18-64 years on index
hospitalization
4,210 Patients with schizophrenia
who meet age criteria with an
index hospitalization
1,284 Excluded patients without
enrollment 24 months prior to index
date
2,926 Patients with schizophrenia
who meet age criteria during index
period with enrollment for 24
months prior

1,600 Continuously enrolled
patients with schizophrenia in
index, pre-index, & who matched
age criteria

1,326 Excluded patients without
enrollment 405 days after index
hospitalization

969 Excluded patients without at
least 2 schizophrenia hospitalizations
during pre-index period

631 Continuously enrolled patients
with schizophrenia in index, preindex, & who matched age and
prior hospitalization criteria

448 Excluded patients without an
SGA or LAI prescription within 40
days of index discharge or with a
LAI prescription before index and
with extensive inpatient use on
index, 60+ days

183 Continuously enrolled patients
with schizophrenia in index and preindex period. Matched age/prior
hospitalization criteria, are prescribed
SGA PO or LAI & naïve to LAIs

23 LAI SGA in
exposure period

135 PO SGA in
exposure period

24

25 PO SGA
patients removed
on aripiprazole
or who switched
to LAI

Figure 2. Study schematic diagram
Pre-index Period

Index Period

Follow-up period

(Jan 1 2010-Dec 31 2011)

(Jan 1 2012-Nov 21 2014)

(Jan 1 2012-Dec 31 2015)

40-day exposure
period

12-month follow-up period

24-month preindex period

Index Date
Most recent ICD-9 295*
hospitalization in
Jan 1 2012-Nov 21
2014

•
•
•
•

Pre-index: 24 months prior to index date
Index date: most recent 295 hospitalization during index period
Exposure period: 40-day exposure window for oral SGA or LAI SGA prescription after
index date discharge
Follow-up: 12 months and 40-days from index date

Figure 3. Decision Tree Diagram
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Figure 4. Sensitivity analysis: tornado diagram
PO Adherence
LAI Adherence
LAI Adherent Stable Cost
Cost
LAI Adherent Switch/Rehospitalization Cost
PO Adherent Stable Cost
Cost
LAI Non-adherent Switch/Rehospitalization Cost
LAI Non-adherent Stable Cost
PO Adherent Switch/Rehospitalization Cost
PO Non-adherent Stable Cost
PO Non-adherent Switch/Rehospitalization Cost

Figure 5. One-way sensitivity analysis: LAI adherence

Proportion of Adherent Patients Receiving LAIs
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